Athersys' MultiStem fails in Phase II, shares crumble


Athersys' (ATHX) MultiStem treatment for ulcerative colitis has failed in a Phase II trial of 88 patients who have become resistant, intolerant or unresponsive to other drugs.

MultiStem didn't significantly reduce the the severity of the disease and rectal bleeding vs a placebo after 8 weeks of treatment.

Despite the results, Athersys intends to publish data from a trial of patients receiving a second round of the therapy, which is also being tested in subjects with certain heart diseases, and immune and neurological disorders.

Athersys' shares are -51.3%. (PR)

Comments (6)
  • cencewolf
    , contributor
    Comments (18) | Send Message
     
    Failed!

     

    Wow, just wow,

     

    The ride was fun, and learned a ton. Thanks everyone for all the input, and on to the next one. Dumped my shares, no longer "long" anything here.. Figured IBD or UC was the "safer" gamble, as opposed to stroke.. Difficult to anticipate positive stroke trials after this as well. Hope you got some of your cash back, as for me? Merely breaking even. Saaaad!
    28 Apr 2014, 10:18 AM Reply Like
  • Mking30
    , contributor
    Comments (142) | Send Message
     
    OMG... My neck... My neck and my back.....Im not feeling good, my heart
    28 Apr 2014, 10:18 AM Reply Like
  • toosmarttofail
    , contributor
    Comments (697) | Send Message
     
    I tried to warn all of you that non-embryonic stemcells are politically motivated snake-oil that lured researchers (other than ACTC's Dr. Lanza) away from the embryonic holy grail. People here were saying $24-26 a share for this turkey, while I noted the history of "nasty retracements" after a rise.

     

    I also said that Phase Ii/III is where adult-cell companies go to die. Maybe now people will believe me, while they still have a third of their money. On the other hand, $1.25 looks pretty cheap right now!
    28 Apr 2014, 10:26 AM Reply Like
  • MoneyGrubber13
    , contributor
    Comments (305) | Send Message
     
    You said it, champ!
    28 Apr 2014, 10:44 AM Reply Like
  • cencewolf
    , contributor
    Comments (18) | Send Message
     
    As soon as ACTC "takes off" and the holy grail gets discovered then you can be the mayor of "i told you so town" toosmarttofail. Frankly, i don't like where either company is right now. Even assuming ACTC IS the "holy grail" as you put it they are very much in a worse place than ATHX,

     

    Dis-illusioned about the potential of adult stem cells? To some degree yes. mislead? I don't think so. We all made a choice, and it didn't pay off. Another day, and only slightly wiser. Still, i don't mind showing the humility here to say this:
    Good job toosmart, you were right that ATHX has clearly failed their phase 2 - i definitely was not anticipating that like you were. May your investments pay off where mine have not.

     

    -Wolf out
    28 Apr 2014, 10:51 AM Reply Like
  • cencewolf
    , contributor
    Comments (18) | Send Message
     
    As soon as ACTC "takes off" and the holy grail gets discovered then you can be the mayor of "i told you so town" toosmarttofail. Frankly, i don't like where either company is right now. Even assuming ACTC IS the "holy grail" as you put it they are very much in a worse place than ATHX,

     

    Dis-illusioned about the potential of adult stem cells? To some degree yes. mislead? I don't think so. We all made a choice, and it didn't pay off. Another day, and only slightly wiser. Still, i don't mind showing the humility here to say this:
    Good job toosmart, you were right that ATHX has clearly failed their phase 2 - i definitely was not anticipating that like you were. May your investments pay off where mine have not.

     

    -Wolf out
    28 Apr 2014, 10:51 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs